
  
    
      
        Background
        <ENAMEX TYPE="SUBSTANCE">Antibody</ENAMEX>-directed enzyme prodrug therapy (<ENAMEX TYPE="ORGANIZATION">ADEPT</ENAMEX>) [ <NUMEX TYPE="CARDINAL">1 2 3</NUMEX>
        <NUMEX TYPE="CARDINAL">4 5</NUMEX> ] is one of the promising new approaches that
        selectively target tumor cells, thus reducing toxic side
        effects to <ENAMEX TYPE="PER_DESC">patients</ENAMEX>. In this approach, an enzyme is
        <ENAMEX TYPE="ORGANIZATION">conjugated</ENAMEX> to a tumor-specific <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX>. The antibody
        selectively localizes the enzyme to the tumor cell surface.
        Subsequent administration of a prodrug substrate of the
        <ENAMEX TYPE="PERSON">enzyme</ENAMEX> leads to the enzyme-catalyzed release of the free
        drug at the tumor site. This strategy addresses the
        stoichiometry, controlled drug release and poor antibody
        penetration problems associated with the use of monoclonal
        <ENAMEX TYPE="SUBSTANCE">antibody-drug</ENAMEX> <ENAMEX TYPE="SUBSTANCE">conjugates</ENAMEX> [ <NUMEX TYPE="CARDINAL">6 7 8</NUMEX> ] . In addition, because
        the process of drug release is enzymatic, a single enzyme
        can generate a large amount of free <ENAMEX TYPE="SUBSTANCE">drug</ENAMEX>. Consequently, a
        small amount of <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> can be used to reduce
        <ENAMEX TYPE="ORGANIZATION">immunogenicity</ENAMEX>.
        It is important that the free <ENAMEX TYPE="SUBSTANCE">drug</ENAMEX> in the <ENAMEX TYPE="ORGANIZATION">ADEPT</ENAMEX> approach
        be highly toxic. Using highly toxic <ENAMEX TYPE="SUBSTANCE">agents</ENAMEX> can reduce the
        amount of the monoclonal <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> required, thereby
        reducing side effects. <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> (Figure <NUMEX TYPE="CARDINAL">1</NUMEX>) is among the most
        potent antitumor <ENAMEX TYPE="PER_DESC">agents</ENAMEX> discovered [ <NUMEX TYPE="CARDINAL">9 10 11 12 13</NUMEX> ] . It
        <ENAMEX TYPE="ORGANIZATION">binds</ENAMEX> to double-stranded B-<ENAMEX TYPE="SUBSTANCE">DNA</ENAMEX> within the minor groove with
        a sequence preference for <TIMEX TYPE="DATE">5</TIMEX>'-d(<ENAMEX TYPE="ORGANIZATION">A/GNTTA</ENAMEX>)-3' and
        <ENAMEX TYPE="PRODUCT">5</ENAMEX>'-d(AAAAA)-3', and alkylates the <NUMEX TYPE="ORDINAL">N3</NUMEX> position of the
        <ENAMEX TYPE="PRODUCT">3</ENAMEX>'-adenine with its left-hand CPI <ENAMEX TYPE="ORG_DESC">segment</ENAMEX> [ <NUMEX TYPE="CARDINAL">14 15</NUMEX> ] .
        <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> also inhibits gene transcription by interfering
        with binding of the <ENAMEX TYPE="DISEASE">TATA box</ENAMEX>-binding <ENAMEX TYPE="SUBSTANCE">protein</ENAMEX> to its target
        <ENAMEX TYPE="SUBSTANCE">DNA</ENAMEX> [ <TIMEX TYPE="DATE">16</TIMEX> ] . Despite its high potency and broad spectrum of
        antitumor activity, <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> cannot be used in humans
        because it causes delayed death in experimental <ENAMEX TYPE="ANIMAL">animals</ENAMEX> [
        <NUMEX TYPE="CARDINAL">17</NUMEX> ] . To pursue <ENAMEX TYPE="PLANT">compounds</ENAMEX> possessing the potent antitumor
        activity but devoid of the toxic side effects of the parent
        compound, many <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">analogues</ENAMEX> have been synthesized [ <NUMEX TYPE="CARDINAL">18</NUMEX>
        <NUMEX TYPE="CARDINAL">19 20 21 22 23 24 25 26</NUMEX> ] .
        Beta-lactamases have been widely investigated for their
        role in the metabolism of antibiotics including
        <ENAMEX TYPE="ORGANIZATION">cephalosporins</ENAMEX> and penicillins. Because of the high
        catalytic efficiency and broad substrate specificity,
        β-lactamases have been extensively used in the <ENAMEX TYPE="ORGANIZATION">ADEPT</ENAMEX>
        approach to activate prodrugs of vinca alkaloids [ <TIMEX TYPE="DATE">27</TIMEX> ] ,
        <ENAMEX TYPE="SUBSTANCE">nitrogen mustard</ENAMEX> [ <NUMEX TYPE="CARDINAL">28 29 30 31 32</NUMEX> ] , doxorubicin [ <NUMEX TYPE="CARDINAL">33 34</NUMEX>
        <NUMEX TYPE="CARDINAL">35 36</NUMEX> ] and others [ <TIMEX TYPE="DATE">37</TIMEX> ] . To take advantage of the potent
        antitumor activity of the <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> class of compounds and
        the <ENAMEX TYPE="ORGANIZATION">ADEPT</ENAMEX> approach, we have synthesized β-lactam prodrugs.
        Herein, we report synthesis and preliminary cytotoxic
        effects of a <ENAMEX TYPE="PER_DESC">prodrug</ENAMEX> comprised of a cephalosporin and a
        <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">analogue</ENAMEX> (Figure <NUMEX TYPE="CARDINAL">1</NUMEX>).
        Prodrug 
        <ENAMEX TYPE="PRODUCT">2</ENAMEX> is expected to be less toxic than its
        corresponding free drug 
        <NUMEX TYPE="CARDINAL">1</NUMEX> . However, it is expected that the
        <ENAMEX TYPE="ORGANIZATION">prodrug</ENAMEX> will be converted to the potent free <ENAMEX TYPE="SUBSTANCE">drug</ENAMEX> by
        β-lactamases localized on the tumor cell surface by an
        <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> (Figure <NUMEX TYPE="CARDINAL">2</NUMEX>). This selective <ENAMEX TYPE="PER_DESC">activation</ENAMEX> of prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> at the tumor site will lead to
        enhanced antitumor therapeutic efficacy.
      
      
        Results and discussion
        Prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> was synthesized as shown in Figure <NUMEX TYPE="CARDINAL">3</NUMEX>.
        The key intermediate, 
        <NUMEX TYPE="CARDINAL">7</NUMEX> , was made using methods developed by
        <ENAMEX TYPE="ORGANIZATION">Jungheim et al.</ENAMEX> [ <TIMEX TYPE="DATE">33</TIMEX> ] , and <ENAMEX TYPE="ORGANIZATION">Rodrigues, et al.</ENAMEX> [ <NUMEX TYPE="CARDINAL">35 36</NUMEX> ]
        with modifications. The spectra data including <ENAMEX TYPE="ORGANIZATION">NMR</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">MS</ENAMEX>
        of compounds 
        <ENAMEX TYPE="PRODUCT">4-7</ENAMEX> were identical to those as
        reported. Compound 
        <NUMEX TYPE="CARDINAL">1</NUMEX> was treated with 
        <NUMEX TYPE="CARDINAL">7</NUMEX> in <ENAMEX TYPE="ORGANIZATION">DMF</ENAMEX> to afford the protected
        prodrug 
        <NUMEX TYPE="CARDINAL">8</NUMEX> . Removal of the t-butyl protection
        <ENAMEX TYPE="ORGANIZATION">group</ENAMEX> from 
        <NUMEX TYPE="CARDINAL">8</NUMEX> generated the targeted prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> with good yield.
        The cytotoxicity of prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> and its corresponding free drug 
        <NUMEX TYPE="CARDINAL">1</NUMEX> was tested against U937 <ENAMEX TYPE="DISEASE">leukemia</ENAMEX>
        cells, and the results are presented in <ENAMEX TYPE="PRODUCT">Table 1</ENAMEX>. When the
        <ENAMEX TYPE="SUBSTANCE">drugs</ENAMEX> were incubated with <NUMEX TYPE="CARDINAL">U937</NUMEX> cells for a period of <NUMEX TYPE="QUANTITY">48-h</NUMEX>,
        prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> (IC 
        <TIMEX TYPE="TIME">50 : 0.9</TIMEX> nM) is <NUMEX TYPE="CARDINAL">10-fold</NUMEX> less toxic than
        its corresponding free drug 
        <NUMEX TYPE="CARDINAL">1</NUMEX> (IC 
        <TIMEX TYPE="TIME">50 : 0.09</TIMEX> nM). As observed for other
        compounds of the <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX> <ENAMEX TYPE="PER_DESC">class</ENAMEX> [ <NUMEX TYPE="CARDINAL">25 37 38</NUMEX> ] , both prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> and the free drug 
        <NUMEX TYPE="CARDINAL">1</NUMEX> caused DNA fragmentation, and the
        cells died by apoptosis (data not shown).
      
      
        Conclusion
        This is the <NUMEX TYPE="ORDINAL">first</NUMEX> report demonstrating synthesis of a
        <ENAMEX TYPE="PER_DESC">prodrug</ENAMEX> comprised of a cephalosporin and a <ENAMEX TYPE="PRODUCT">CC-1065</ENAMEX>
        <ENAMEX TYPE="ORGANIZATION">analogue</ENAMEX>. The preliminary in vitro studies show the prodrug
        to be less toxic than the free <ENAMEX TYPE="SUBSTANCE">drug</ENAMEX>. Due to the slow
        non-enzymatic degradation of the cephalosporins in solution
        [ <TIMEX TYPE="DATE">39</TIMEX> ] , the ratio of toxicity of cephalosporin-containing
        <ENAMEX TYPE="ORGANIZATION">prodrugs</ENAMEX> to their corresponding free <ENAMEX TYPE="SUBSTANCE">drugs</ENAMEX> is generally not
        very high. However, some of the prodrugs are very effective
        against tumors in <ENAMEX TYPE="ANIMAL">mouse</ENAMEX> models. For example, a
        cephalosporin-doxorubicin prodrug was <NUMEX TYPE="CARDINAL">9</NUMEX>-fold less toxic
        than free doxrubicin against tumor cells in vitro, but
        caused <ENAMEX TYPE="DISEASE">tumor regression</ENAMEX> when tested in tumor xenograft
        models [ <TIMEX TYPE="DATE">40</TIMEX> ] . A cephalosporin-vinca alkaloid prodrug was
        <NUMEX TYPE="CARDINAL">5</NUMEX>-fold less toxic than the free <ENAMEX TYPE="SUBSTANCE">drug</ENAMEX> against tumor cells in
        <ENAMEX TYPE="ORGANIZATION">vitro</ENAMEX>, but was highly effective in tumor xenograft models
        in vivo [ <TIMEX TYPE="DATE">41</TIMEX> ] . When taxol was conjugated to a
        cephalosporin, the resulting prodrug was approximately
        <NUMEX TYPE="CARDINAL">10-fold</NUMEX> less toxic than free taxol against tumor cells in
        <ENAMEX TYPE="ORGANIZATION">vitro</ENAMEX> [ <TIMEX TYPE="DATE">36</TIMEX> ] . Thus, prodrug 
        <ENAMEX TYPE="PRODUCT">2</ENAMEX> has the potential to be useful in
        <ENAMEX TYPE="DISEASE">cancer</ENAMEX> treatment using the <ENAMEX TYPE="ORGANIZATION">ADEPT</ENAMEX> approach. We will report
        more biological data in due course.
      
      
        Materials and methods
        Cephalothin sodium, 
        <NUMEX TYPE="CARDINAL">3</NUMEX> , (<NUMEX TYPE="CARDINAL">2.5</NUMEX> <ENAMEX TYPE="ORGANIZATION">g</ENAMEX>, <NUMEX TYPE="MONEY">5.98 mmol</NUMEX>) was suspended in
        <ENAMEX TYPE="ORGANIZATION">dichloromethane</ENAMEX> (<NUMEX TYPE="MONEY">150 mL</NUMEX>). Anhydrous <ENAMEX TYPE="SUBSTANCE">hydrogen chloride</ENAMEX> (<NUMEX TYPE="CARDINAL">4</NUMEX> <ENAMEX TYPE="ORGANIZATION">N</ENAMEX>
        in dioxane, <NUMEX TYPE="CARDINAL">2</NUMEX> mL, <NUMEX TYPE="CARDINAL">8</NUMEX> mmol) was added, and the reaction
        <ENAMEX TYPE="PERSON">mixture</ENAMEX> was stirred for <TIMEX TYPE="TIME">30 min</TIMEX> at room temperature. 
        tert -Butyl trichloroacetimidate (<NUMEX TYPE="CARDINAL">3.2</NUMEX>
        mL, <NUMEX TYPE="MONEY">17.84 mmol</NUMEX>) was added, and the reaction mixture was
        stirred <TIMEX TYPE="TIME">overnight</TIMEX> at room temperature. The reaction mixture
        was washed consecutively with <ENAMEX TYPE="SUBSTANCE">water</ENAMEX> (<NUMEX TYPE="MONEY">150 mL</NUMEX>), saturated
        sodium <ENAMEX TYPE="SUBSTANCE">hydrogen carbonate solution</ENAMEX> (<NUMEX TYPE="MONEY">150 mL</NUMEX>) and <ENAMEX TYPE="SUBSTANCE">water</ENAMEX> (<ENAMEX TYPE="CONTACT_INFO">150</ENAMEX>
        <ENAMEX TYPE="ORGANIZATION">mL</ENAMEX>). The organic <ENAMEX TYPE="SUBSTANCE">solution</ENAMEX> was dried using sodium <ENAMEX TYPE="SUBSTANCE">sulfate</ENAMEX>.
        The solvent was removed, and the product was purified by
        flash column chromatography eluting with a solvent
        consisting of dichloromethane, ethyl acetate and hexane
        (<NUMEX TYPE="MONEY">1/1/3</NUMEX>, <ENAMEX TYPE="PRODUCT">v/v</ENAMEX>) affording <NUMEX TYPE="QUANTITY">1.2 g</NUMEX> of 
        <NUMEX TYPE="CARDINAL">4</NUMEX> (<NUMEX TYPE="PERCENT">44%</NUMEX> yield).
        Compound 
        <NUMEX TYPE="CARDINAL">4</NUMEX> (<NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">g</ENAMEX>, <NUMEX TYPE="MONEY">2.21 mmol</NUMEX>) was dissolved in
        <ENAMEX TYPE="PERSON">methanol</ENAMEX> (<NUMEX TYPE="MONEY">70 mL</NUMEX>), and solid potassium carbonate (<NUMEX TYPE="MONEY">120 mg</NUMEX>)
        was added. The mixture was stirred for <TIMEX TYPE="TIME">2 h</TIMEX> at room
        <ENAMEX TYPE="PERSON">temperature</ENAMEX>, and <ENAMEX TYPE="SUBSTANCE">acetic acid</ENAMEX> (<ENAMEX TYPE="CONTACT_INFO">200 μL</ENAMEX>) was added to quench
        the reaction. The solvent was removed, and the product was
        purified by flash column chromatography eluting with <NUMEX TYPE="PERCENT">8%</NUMEX>
        <ENAMEX TYPE="ORGANIZATION">acetone</ENAMEX> in dichloromethane to afford <NUMEX TYPE="CARDINAL">220</NUMEX> mg of 
        <NUMEX TYPE="CARDINAL">5</NUMEX> (<NUMEX TYPE="PERCENT">24%</NUMEX> yield).
        Compound 
        <NUMEX TYPE="CARDINAL">5</NUMEX> (<NUMEX TYPE="CARDINAL">280</NUMEX> mg, <NUMEX TYPE="MONEY">0.68 mmol</NUMEX>) was dissolved in
        <ENAMEX TYPE="ORGANIZATION">anhydrous THF</ENAMEX> (<NUMEX TYPE="MONEY">40 mL</NUMEX>), and dimethylaminopyridine (<NUMEX TYPE="MONEY">1 mg</NUMEX>),
        <ENAMEX TYPE="ORGANIZATION">p-nitrophenylchloroformate</ENAMEX> (<NUMEX TYPE="CARDINAL">0.2</NUMEX> <ENAMEX TYPE="ORGANIZATION">g</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> mmol) and <NUMEX TYPE="CARDINAL">2</NUMEX>,
        <TIMEX TYPE="TIME">6-lutidine</TIMEX> (<ENAMEX TYPE="CONTACT_INFO">120 μL</ENAMEX>), <NUMEX TYPE="CARDINAL">1</NUMEX> mmol) were added sequentially. The
        reaction mixture was stirred <TIMEX TYPE="TIME">overnight</TIMEX> at room temperature.
        The solvent was removed, and the product was purified by
        flash column chromatography eluting with <NUMEX TYPE="PERCENT">5%</NUMEX> ethyl acetate
        in dichloromethane to afford <NUMEX TYPE="CARDINAL">271</NUMEX> mg of 
        <NUMEX TYPE="CARDINAL">6</NUMEX> (<NUMEX TYPE="PERCENT">69%</NUMEX> yield).
        To a solution of 
        <NUMEX TYPE="CARDINAL">6</NUMEX> (<NUMEX TYPE="MONEY">50 mg</NUMEX>, <NUMEX TYPE="QUANTITY">87 μmol</NUMEX>) in dichloromethane
        (<NUMEX TYPE="MONEY">2 mL</NUMEX>) cooled to <TIMEX TYPE="DATE">0°C</TIMEX> was added 
        <ENAMEX TYPE="PRODUCT">m-</ENAMEX> <ENAMEX TYPE="SUBSTANCE">chloroperoxybenzoic acid</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">CPBA</ENAMEX>, <NUMEX TYPE="CARDINAL">26</NUMEX>
        mg, <NUMEX TYPE="QUANTITY">93 μmol</NUMEX>) in <NUMEX TYPE="CARDINAL">0.5</NUMEX> mL of dichloromethane. The reaction
        <ENAMEX TYPE="PERSON">mixture</ENAMEX> was stirred for <TIMEX TYPE="TIME">15 min</TIMEX> at <TIMEX TYPE="DATE">0°C</TIMEX>, and was then washed
        with <NUMEX TYPE="PERCENT">5%</NUMEX> potassium <ENAMEX TYPE="SUBSTANCE">hydrogen carbonate solution</ENAMEX> followed by
        <ENAMEX TYPE="SUBSTANCE">brine</ENAMEX>. The solvent was removed, and the product was
        purified by flash column chromatography eluting with <NUMEX TYPE="PERCENT">8%</NUMEX>
        <ENAMEX TYPE="ORGANIZATION">ethyl</ENAMEX> acetate in dichloromethane to afford <NUMEX TYPE="CARDINAL">34</NUMEX> mg of 
        <NUMEX TYPE="CARDINAL">7</NUMEX> (<NUMEX TYPE="PERCENT">66%</NUMEX> yield).
        Compound 
        <NUMEX TYPE="CARDINAL">7</NUMEX> (<NUMEX TYPE="MONEY">15 mg</NUMEX>, <NUMEX TYPE="QUANTITY">25 μmol</NUMEX>) was added to a
        solution of 
        <NUMEX TYPE="CARDINAL">1</NUMEX> (<NUMEX TYPE="CARDINAL">9</NUMEX> mg, <NUMEX TYPE="QUANTITY">23 μmol</NUMEX>) in <ENAMEX TYPE="ORGANIZATION">DMF</ENAMEX> (<NUMEX TYPE="MONEY">0.3 mL</NUMEX>),
        which was synthesized as we reported previously [ <TIMEX TYPE="DATE">20</TIMEX> ] ,
        and the reaction mixture was stirred <TIMEX TYPE="TIME">overnight</TIMEX> at room
        temperature. The product was purified by thin layer
        chromatography eluting with ethyl acetate and hexane (<NUMEX TYPE="MONEY">3/1</NUMEX>,
        <ENAMEX TYPE="PRODUCT">v/v</ENAMEX>) to afford <NUMEX TYPE="CARDINAL">12</NUMEX> mg of 
        <NUMEX TYPE="CARDINAL">8</NUMEX> (<NUMEX TYPE="PERCENT">62%</NUMEX> yield). 1H <ENAMEX TYPE="ORGANIZATION">NMR</ENAMEX> (DMF-d 
        <NUMEX TYPE="CARDINAL">7</NUMEX> , ppm): <NUMEX TYPE="MONEY">10.70</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="MONEY">9.15</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="MONEY">8.63</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">8.25</NUMEX>-<NUMEX TYPE="CARDINAL">7.85</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">4</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">7.60</NUMEX>-<NUMEX TYPE="CARDINAL">7.19</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">7</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="CARDINAL">7.05</NUMEX>-<NUMEX TYPE="CARDINAL">6.95</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">2</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">6.05</NUMEX>-<NUMEX TYPE="CARDINAL">6.01</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">5.39</NUMEX>-<NUMEX TYPE="CARDINAL">5.30</NUMEX> (<ENAMEX TYPE="GPE">d</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="CARDINAL">5.12</NUMEX>-<NUMEX TYPE="CARDINAL">4.79</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">5</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">4.35</NUMEX>-<NUMEX TYPE="CARDINAL">4.27</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">4.19</NUMEX>-<NUMEX TYPE="CARDINAL">3.75</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">6</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="MONEY">1.58</NUMEX> (s, <NUMEX TYPE="CARDINAL">9</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>). <ENAMEX TYPE="PRODUCT">FAB MS</ENAMEX> 
        <ENAMEX TYPE="PRODUCT">m/e 866.0</ENAMEX> (<ENAMEX TYPE="PRODUCT">M + Na</ENAMEX>) +.
        To a solution of 
        <NUMEX TYPE="CARDINAL">8</NUMEX> (<NUMEX TYPE="CARDINAL">5</NUMEX> mg, <NUMEX TYPE="QUANTITY">5.9 μmol</NUMEX>) in <ENAMEX TYPE="ORGANIZATION">DMF</ENAMEX> (<NUMEX TYPE="MONEY">0.2 mL</NUMEX>) and
        <ENAMEX TYPE="ORGANIZATION">dichloromethane</ENAMEX> (<NUMEX TYPE="MONEY">1 mL</NUMEX>) was added trifluroacetic <ENAMEX TYPE="SUBSTANCE">acid</ENAMEX> (<ENAMEX TYPE="CONTACT_INFO">1</ENAMEX>
        <ENAMEX TYPE="ORGANIZATION">mL</ENAMEX>), and the solution was stirred for <TIMEX TYPE="TIME">2 h</TIMEX> at room
        temperature. The solvent was removed, and <ENAMEX TYPE="SUBSTANCE">ethyl ether</ENAMEX> was
        added. The solid was filtered, and washed with ether to
        afford prodrug 
        <NUMEX TYPE="CARDINAL">2</NUMEX> (<NUMEX TYPE="MONEY">3.7 mg</NUMEX>, <NUMEX TYPE="PERCENT">79%</NUMEX> yield). 1H <ENAMEX TYPE="ORGANIZATION">NMR</ENAMEX> (DMF-d 
        <NUMEX TYPE="CARDINAL">7</NUMEX> , ppm): <NUMEX TYPE="MONEY">11.56</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="MONEY">10.50</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX>
        <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="MONEY">9.65</NUMEX> (s, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">8.25</NUMEX>-<NUMEX TYPE="CARDINAL">7.85</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">4</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">7.60</NUMEX>-<NUMEX TYPE="CARDINAL">7.24</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">7</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="CARDINAL">7.10</NUMEX>-<NUMEX TYPE="CARDINAL">6.96</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">2</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">6.10</NUMEX>-<NUMEX TYPE="CARDINAL">6.01</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">5.42</NUMEX>-<NUMEX TYPE="CARDINAL">5.38</NUMEX> (<ENAMEX TYPE="GPE">d</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>),
        <NUMEX TYPE="CARDINAL">5.10</NUMEX>-<NUMEX TYPE="CARDINAL">4.60</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">5</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">4.35</NUMEX>-<NUMEX TYPE="CARDINAL">4.25</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>), <NUMEX TYPE="CARDINAL">4.20</NUMEX>-<NUMEX TYPE="CARDINAL">3.75</NUMEX> (<ENAMEX TYPE="ORGANIZATION">m</ENAMEX>, <NUMEX TYPE="CARDINAL">6</NUMEX> <ENAMEX TYPE="ORGANIZATION">H</ENAMEX>).
        <ENAMEX TYPE="PRODUCT">FAB MS</ENAMEX> 
        <ENAMEX TYPE="PRODUCT">m/e 787.1</ENAMEX>.
      
    
  
